New Protocol: First-line regorafenib with nivolumab and chemotherapy in advanced esophageal, gastric, or gastro-esophageal junction cancer

Single-arm, single-center, phase 2 trial

Previously untreated advanced oesophageal, gastric, or gastro-oesophageal junction cancer

Nivolumab + FOLFOX + Regofenib (n=35)

BmOS: NR, 12 mos OS: 85% [74-98]

mPFS: 13.0 mos [7.6-NR], 12 mos PFS: 51% [37-71]

ORR:76% [22 of 35 pts], CR: 10% [3 of 35 pts]

Grade≥ 3: Neutropenia (46%), hypertension (15%), dry skin, pruritus (13%), anemia (10%)

Cytryn L. Samuel et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-center, phase 2 trial,

Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023